Skip to main content
. 2011 Jun 15;7(3):282–292. doi: 10.5664/JCSM.1074

Figure 3.

Figure 3

Proportion of responders (much or very much improved) on the investigator-rated CGI-I by visit (mITT population)

Adjusted odds ratios for GEn compared with placebo at Week 12 LOCF: Co-primary endpoint: GEn 1200 mg, 4.3 (95% CI: 2.34, 7.86; p < 0.0001); Secondary endpoint: GEn 600 mg, 3.3 (95% CI: 1.84, 5.99; p < 0.0001). aObserved case. ***p < 0.0001; **p < 0.001; *p < 0.01; †p < 0.05 compared with placebo. CI, confidence interval; CGI-I, Clinical Global Impression–Improvement scale; GEn, gabapentin enacarbil; LOCF, last observation carried forward; mITT, modified intent-to-treat.